• Follow us

Who we are

Governance

Christophe Nicoli

Chief Executive Officer

Emmanuelle Camus-Nikitine

Group General Counsel

Christophe Muguet

Chief Operating Officer

Laurent Zuber

Chief Commercial Officer & General Manager West World

Jérôme Brassens

Chief Financial Officer

Pierre-Michel Bataillard

Chief Human Resources Officer

Frédéric Barbier

General Manager China / Asia-Pacific

Carole Grassi Mircich

Chief Innovation & Development Officer

Akshay Singh

General Manager India

Key facts

Business data

Turnover: 347.5 M€
 

Global production capacity:
+ 2 Billion vials per day

5 plants
7 furnaces
1 sorting facility
1 decoration workshop

Geographical areas: worldwide scope
90 agents & distributors
10 sales offices

Social data

3000 employees

3000+ employees
32% of women in top
management positions

2135 perm contracts

2135 perm contracts
944 temporary contracts
369 person recruited in 2020

Environmental data

-18% ​water consumption

-18%
water consumption

-1,5% ​GHG emissions on our European perimeter

-1,5%
GHG emissions on our European perimeter

+ 41% of recycled waste

+ 41%
of recycled waste

Discover the full CSR report

Milestones

2021PAI Partners (PAI)

PAI Partners (PAI), a leading European private equity firm, becomes SGD Pharma new shareholder.​

2021

Ecovadis Platinum medal - The group was awarded the Ecovadis Platinum medal, its Chinese plant and its subsidiary Embelia were both awarded the Silver medal.

2021

Introduction of Type I molded glass enhanced offer: three distinct solutions - AXess, AXecure and AXpert - to help customers make an optimized choice, well-matched for specific requirements.​

2021

Ambitious capacity extension plan of Vemula plant (tubular) to reach a tubular production capacity of 1 billion pieces by 2024. 

2021

SGD Pharma starts a major Sucy-en-Brie plant development project, investing over 31M€ to rebuild one of the furnaces and modernize the site.​

2020

Introduction of Ensiemo, the new complete child-resistant packaging solution for CBD oils. Combining the company’s extensive pharmaceutical packaging expertise with the need for compliant, safe packaging for CBD oils, SGD Pharma has developed its first complete packaging solution & services, Ensiemo: a wide range of dropper bottles and dropper, in clear or amber glass.

2019

As part of its continuous improvement program, SGD Pharma optimized in 2020 the clear Type I glass composition of its best-in-class manufacturing plant at Saint-Quentin-Lamotte. This implementation provides a more robust process to improve the stability of the glass quality, improves the chemical resistance to reduce interaction with sensitive drug formulation and answers to stricter regulatory requirements.

2018

Introduction of Sterinity. The Sterinity platform in partnership with Stevanato Group – a recognized RTU platform for injectable vials by the pharmaceutical industry - offers high quality pre-sterilized Type I molded glass to speed up aseptic filling processes and reduces time-to-market for high value parenteral drugs.

2017

India plant's new Unit V is fully operational and 100% dedicated to our tubular product range.

2017

Launch of Clareo. This new innovative range of vials offers a combination of homogeneous wall thickness and superior cosmetic quality, which is unique for the molded glass Type II market. Improved mechanical resistance, significant reduction in the breakage rate and improved inspectability are the main characteristics of Clareo.

2017

SGD Pharma unveils​ its new identity​. The new mission, vision and guiding principles support an ambitious growth strategy and a long-term vision for SGD Pharma.

2016

JIC (China Jianyin Investment Ltd) becomes SGD Group new shareholder.

2015

The new plant at Saint-Quentin-Lamotte produces its first glass vial on September 11th. December 21st marks the end of the pharmaceutical glass production at Mers-les-Bains after 57 years dedicated to this activity.

2014

New manufacturing factory in Picardie at Saint-Quentin-Lamotte. SGD launched the newest, most modern plant in the world to manufacture molded glass pharmaceutical packaging. The construction lasted 13 months. The 13-hectare site benefits from a state-of-the art equipment (electrical and oxy-gaz furnaces) enabling an outage daily capacity of 1 million bottles and 20.000 tons per year.

2013

The acquisition of an India-based manufacturer of Type I allows SGD Pharma to enter the tubular conversion market and to serve the fast-growing Indian pharmaceutical market.

2011

Introduction of EasyLyo. EasyLyo provides a stronger packaging that is more resistant and suitable to extreme conditions encountered during the lyophilization process. EasyLyo is a range of Type I glass vials combining the strength of molded glass with superior cosmetic quality and weight reduction.

2010

Oaktree Capital Management Ltd, an American investment firm, enters the Group’s capital on February 4th.

2008

Acquisition of the Société de Services Verriers (SSV) company in France, dedicated to the sorting of pharmaceutical containers, which is a new activity for SGD Pharma.

2007

Saint-Gobain Desjonquères becomes SGD Group. SGD Pharma is the first molded glass manufacturer to obtain the ISO 15378 certifications for all its pharmacy sites.

2005

U-Save launch. The U-Save range is dedicated to nasal applications. The specific design of the U-Save molded vials provides 100% of product recovery for high value nasal spray drugs. Can be customised with plastic coating and/or decoration.

1972

The acquisition of the Henri Desjonquères company by Saint-Gobain gives birth to Saint-Gobain Desjonquères, increasing its number of manufacturing sites worldwide: Kipfenberg (Germany), Santa Marina (Brazil), La Granja (Spain).

1958

The furnace 4 at the Mers-les-Bains (France) factory is dedicated to the production of Type I molded glass.

1939

Automation of the Mers-les-Bains (France) factory with IS machines.

1917

Specialization of the factory in Sucy-en-Brie (France) in the production of pharmaceutical bottles in molded glass.

1896

Henri Desjonquères founds Verrerie du Tréport, a glass manufacture factory in Mers-les-Bains (France), primarily aimed at the luxury perfumery market. The molded glass bottles are hand-blown.

Corporate Strategy

Corporate Strategy

Discover SGD Pharma corporate strategy, mission and values.

Read more
Innovations

Innovations

One of the keys to SGD Pharma’s leadership position in the glass industry has always been its drive to continually innovate.

Read more
SGD Pharma markets

Markets

Use our sector-specific webpages to find the best glasspackaging solution for your product. 

Read more